Novel N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives were synthesized and evaluation of their anticonvulsant effects was done using various models of experimental epilepsy. Initial anticonvulsant activities of the compounds were investigated using intraperitoneal (i.p.) maximal electroshock shock (MES), subcutaneous pentylenetetrazole (scPTZ) seizure models in mice. The quantitative assessment after oral administration in rats showed that the most active was 2-methyl-4-oxo-N-(6-(trifluoromethoxy)benzo[d]thiazol-2-ylcarbamoyl)quinazoline-3(4H)-carbothioamide (SA 24) with ED₅₀ values of 82.5 μmol/kg (MES) and 510.5 μmol/kg (scPTZ). This molecule was more potent than phenytoin and ethosuximide which were used as reference antiepileptic drugs. To explain the possible mechanism for anticonvulsant action, some of the selected active compounds were subjected to GABA (γ-amino butyric acid) assay and AMPA ((S)-2-amino-3-(3-hydroxyl-5-methyl-4-isoxazolyl) propionic acid) induced seizure test.

合成了新的N-（苯并[ d ]噻唑-2-基氨基甲酰基）-2-甲基-4-氧代喹唑啉-3（4 H）-碳硫代酰胺衍生物，并使用各种实验性癫痫模型评估了它们的抗惊厥作用。使用小鼠腹膜内（ip）最大电击休克（MES），皮下戊二烯四唑（sc PTZ）癫痫发作模型研究了化合物的初始抗惊厥活性。大鼠口服给药后的定量评估表明，活性最高的是2-甲基-4-氧代-N-（6-（三氟甲氧基）苯并[ d ]噻唑-2-基氨基甲酰基）喹唑啉-3（4 H）-甲硫酰胺（SA 24）和ED_50个值分别为82.5μmol/ kg（MES）和510.5μmol/ kg（sc PTZ）。该分子比用作参考抗癫痫药的苯妥英钠和乙巯乙酰亚胺更有效。为了解释抗惊厥作用的可能机理，对一些选定的活性化合物进行了GABA（γ-氨基丁酸）测定和AMPA（（S）-2-氨基-3-（3-羟基-5-甲基-4） -异恶唑基）丙酸）诱发的癫痫发作测试。